Form 4 Filing for Altimmune, Inc. (ALT)

This filing details transactions by Gregory Weaver, Chief Financial Officer of Altimmune, Inc. On October 1, 2026, Mr. Weaver acquired 14,475 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) with a reported transaction price of $0.00. This acquisition increased his post-transaction shares to 54,306. Concurrently, 4,379 shares were disposed of, with a transaction price of $2.76 per share, resulting in 49,927 shares remaining. The RSUs vest over four years, with 25% vesting on October 1, 2026, and the remainder vesting annually over the following three years, contingent on continued service. The disposal of shares was to cover taxes associated with the RSU vesting. Each RSU represents a contingent right to one share of Common Stock upon vesting.